2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (PyL) in Patients With High Risk and Biochemically Recurrent Prostate Cancer
| Registry | NCT04700332 |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional; non randomized, parallel, masking: none, diagnostic |
| Enrollment | 184 (Estimated) |
| Sponsor | Hoag Memorial Hospital Presbyterian (Other) |
| Conditions | Prostate Cancer |
| Interventions | DCFPyL PET/CT (Drug) |
| Dates | start 2021-02-01, primary completion 2022-07-15 (estimated), completion 2022-12-15 (estimated), first posted 2021-01-07, last updated 2021-07-27 |
| Locations | 1 site in United States |
Related Papers Related Patents Related Grants Related Experts
All trials for Prostate Cancer All trials of DCFPyL PET/CT
The standard of care imaging of prostate cancer metastases recommended by the National Comprehensive Cancer Network (NCCN), CT of the chest/abdomen/pelvis and bone scan, may be suboptimal. PyL is a novel PET tracer designed to detect prostate specific membrane antigen (PSMA) expressed on prostate cancer cells. PyL PET/CT may provide improved evaluation of clinically significant metastases in patients with prostate cancer.
This will be a phase II clinical trial to assess the clinical value of PyL for detection of disease in pateints with:
1. High risk prostate cancer and planned prostatectomy or radiation therapy (arm 1) and
2. Biochemically recurrent prostate cancer (arm 2) but without evidence of disease of standard of care imaging (CT of the chest/abdomen/pelvis and bone scan).
In both cohorts, PyL PET/CT will be obtained and evaluated by a nuclear radiologist trained in novel PET radiotracers, including PyL. Lesions suspicious for disease of PyL that were unsuspected on standard of care imaging will be selected for biopsy for pathologic confirmation if feasible . Pathology will be used as the reference standard for confirming malignancy.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| High risk prostate cancer | Experimental | Drug: DCFPyL PET/CT | DCFPyL PET/CT will be compared to CT/bone scan for detection of unsuspected metastases in patients with high risk prostate cancer and planned prostatectomy or or radiation therapy |
| Biochemically recurrent prostate cancer | Experimental | Drug: DCFPyL PET/CT | DCFPyL PET/CT will be utilized for detection of unsuspected metastases in patients with biochemically recurrent prostate cancer, but with no evidence of disease on CT/bone scan. |
Sex: Male, ages: 18 Years to any
Inclusion Criteria: 1. Male ≥ 18 years of age. 2. Histologically confirmed adenocarcinoma of the prostate 3. Patients meet one of the follow criteria: Cohort 1: High risk prostate cancer (PSA >10, Gleason 8-10, or clinical stage >T2c) and planned prostatectomy or radiation therapy or Cohort 2: Biochemical prostate cancer relapse (Prostate Specific Antigen (PSA) > 0.2 ng/ml in patients following prostatectomy or ≥ 2 ng/ml more than the PSA nadir in patient following radiotherapy, as defined by the ASTRO-Phoenix criteria \[18\] and no evidence of malignancy on standard of care imaging for metastases (CT of the chest/abdomen/pelvis and bone scan) within 3 months. Exclusion Criteria: 1. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. 2. Patients who cannot undergo PET/CT scanning because of weight limits. PET/CT scanners may not be able to function with patients over 450 pounds. 3. Change in therapy since standard of care imaging
| Facility | City | Country | Status |
|---|---|---|---|
| Hoag Memorial Hospital Presbyterian | Irvine, California | United States | Recruiting |